RxDoctor Payments Data

Julie Kraeger

Nurse Practitioner · Lowville, NYNPI 1639664477

Payments from drug & device makers

$1,413in general payments, 2019–2025

Across 73 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$386
  • AbbVie$266
  • Lilly USA, LLC$179
  • AstraZeneca$116
  • Amgen$114
  • Exact Sciences$77
  • plus $275 from 9 others

What the payments were for

  • Food & beverage$1,413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,413 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$30,513
Medicare patients
192
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$70,562
EliquisApixaban49$60,581
OzempicSemaglutide29$40,360
TrulicityDulaglutide17$24,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$18,771
Soliqua 100-33Insulin Glargine/Lixisenatide16$16,766
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$3,636
Albuterol Sulfate HfaAlbuterol Sulfate61$2,236
Omeprazole127$1,582
Atorvastatin Calcium149$1,357
Gabapentin50$1,031
Rosuvastatin Calcium104$958
Levothyroxine Sodium54$898
Sucralfate12$896
Pregabalin18$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$60,58149 claims
Novo NordiskOzempic$386$40,36029 claims
Lilly USA, LLCTrulicity$179$24,42117 claims
GSKTrelegy Ellipta$64$18,77114 claims
AbbVieSynthroid$266$43818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Lowville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →